Exploiting drug repositioning for discovery of a novel HIV combination therapy

Journal of Virology

Volumn 84, Issue 18, 2010, Pages 9301-9309

  Clouser, Christine L ^a,b   Patterson, Steven E ^c   Mansky, Louis M ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; 5 AZA 2' DEOXYCYTIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZACITIDINE; CYTARABINE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; GUANAZOLE; HYDROXYUREA; LUTEOLIN; METHOTREXATE; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG; DEOXYCYTIDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROVIRUS; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; HIV INFECTIONS; HUMAN; PROCEDURES;

ANTI-HIV AGENTS; AZACITIDINE; DEOXYCYTIDINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; MUTATION;

EID: 77956040787     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01006-10     Document Type: Article

References (42)

1. Ashburn, T. T., and K. B. Thor. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3:673-683.
2. Baba, M., R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, and J. Desmyter. 1987. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′- deoxynucleosides but enhances inhibitory effects of purine 2′,3′- dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31:1613-1617.
3. Balzarini, J., D. A. Cooney, M. Dalal, G.-J. Kang, J. E. Cupp, E. De Clercq, S. Broder, and D. G. Johns. 1987. 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32: 798-806.
4. Bebenek, K., J. D. Roberts, and T. A. Kunkel. 1992. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 267:3589-3596.
5. Bednarik, D. P., J. A. Cook, and P. M. Pitha. 1990. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J. 9:1157-1164.
6. Carr, B. I., S. Rahbar, Y. Asmeron, A. Riggs, and C. D. Winberg. 1988. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br. J. Cancer 57:395-402.
7. Casabianca, A., C. Orlandi, A. Fraternale, and M. Magnani. 2004. Development of a real-time PCR assay using SYBR Green I for provirus load quantification in a murine model of AIDS. J. Clin. Microbiol. 42:4361-4364.
8. Christman, J. K. 2002. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483-5495.
9. Dapp, M. J., C. L. Clouser, S. Patterson, and L. M. Mansky. 2009. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 83:11950-11958.
10. Gao, W.-Y., D. G. Johns, M. Tanaka, and H. Mitsuya. 1999. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine. Mol. Pharmacol. 55:535-540.
11. Gao, W. Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U. S. A. 90:8925-8928.
12. Garg, S., R. Kandarapu, K. Vermani, K. R. Tambwekar, A. Garg, D. P. Waller, and L. J. Zaneveld. 2003. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 17:17-32.
13. Grande-Pérez, A., E. Lazaro, P. R. Lowenstein, E. Domingo, and S. C. Manrubia. 2005. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U. S. A. 102:4448-4452.
14. Grunewald, R., H. Kantarjian, M. Du, K. Faucher, P. Tarassoff, and W. Plunkett. 1992. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J. Clin. Oncol. 10:406-413.
15. Harrington, R. D., and A. P. Geballe. 1993. Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J. Virol. 67:5939-5947.
16. Harris, K. S., W. Brabant, S. Styrchak, A. Gall, and R. Daifuku. 2005. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 67:1-9.
17. He, J., S. Choe, R. Walker, P. Di Marzio, D. O. Morgan, and N. R. Landau. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:6705-6711.
18. Heinemann, V., Y.-Z. Xu, S. Chubb, A. Sen, L. W. Hertel, G. B. Grindey, and W. Plunkett. 1990. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 38:567-572.
19. Holland, J. J., E. Domingo, J. C. De La Torre, and D. A. Steinhauer. 1990. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 64:3960-3962.
20. Horwitz, J. P., J. Chua, and M. Noel. 1964. Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymine. J. Org. Chem. 29:2076-2078.
21. Hsie, A. W., D. A. Casciano, D. B. Couch, D. F. Krahn, J. P. O'Neill, and B. L. Whitfield. 1981. The use of Chinese hamster ovary cells to quantify specific locus mutation and to determine mutagenicity of chemicals. A report of the gene-tox program. Mutat. Res. 86:193-214.
22. Huang, P., S. Chubb, L. W. Hertel, G. B. Grindey, and W. Plunkett. 1991. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51: 6110-6117.
23. Jackson-Grusby, L., P. W. Laird, S. N. Magge, B. J. Moeller, and R. Jaenisch. 1997. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl. Acad. Sci. U. S. A. 94:4681-4685.
24. Lin, T.-S., and W. H. Prusoff. 1978. Synthesis and biological activity of several amino analogues of thymidine. J. Med. Chem. 21:109-112.
25. Loeb, L. A., J. M. Essigmann, F. Kazazi, J. Zhang, K. D. Rose, and J. I. Mullins. 1999. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U. S. A. 96:1492-1497.
26. Lori, F., A. Malykh, A. Cara, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. 1994. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805.
27. Martinez, M. A., J.-P. Vartanian, and S. Wain-Hobson. 1994. Hypermutagenesis of RNA using human immunodeficiency virus type 1 and biased dNTP concentrations. Proc. Natl. Acad. Sci. U. S. A. 91:11787-11791.
28. Meyerhans, A., J.-P. Vartanian, C. Hultgren, U. Plikat, A. Karlsson, L. Wang, S. Eriksson, and S. Wain-Hobson. 1994. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-540.
29. Mini, E., S. Nobili, B. Caciagli, I. Landini, and T. Mazzei. 2006. Cellular pharmacology of gemcitabine. Ann. Oncol. 17:v7-v12.
30. Momparler, R. L. 2005. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin. Hematol. 42:S9-S16.
31. Momparler, R. L., D. Y. Bouffard, L. F. Momparler, J. Dionne, K. Belanger, and J. Ayoub. 1997. Pilot phase I-II study on 5-aza-2′- deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8:358-368. (Pubitemid 27204954)
32. Momparler, R. L., J. Samson, L. F. Momparler, and G. E. Rivard. 1984. Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother. Pharmacol. 13:191-194.
33. Oki, Y., E. Aoki, and J. P. Issa. 2007. Decitabine - bedside to bench. Crit. Rev. Oncol. Hematol. 61:140-152.
34. Pariente, N., A. Airaksinen, and E. Domingo. 2003. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J. Virol. 77:7131-7138. (Pubitemid 36666908)
35. Pariente, N., S. Sierra, P. R. Lowenstein, and E. Domingo. 2001. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 75:9723-9730.
36. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
37. Ruiz-Jarabo, C. M., C. Ly, E. Domingo, and J. C. Torre. 2003. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308:37-47.
38. Sierra, S., M. Davila, P. R. Lowenstein, and E. Domingo. 2000. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol. 74:8316-8323.
39. Snyder, R. D., and P. J. Lachmann. 1989. Differential effects of 5-azacytidine and 5-azadeoxycytidine on cytotoxicity, DNA-strand breaking and repair of X-ray-induced DNA damage in HeLa cells. Mutat. Res. 226:185-190.
40. Sugiyama, E., N. Kaniwa, S. Ryang Kim, R. Kikura-Hanajiri, R. Hasegawa, K. Maekawa, Y. Saito, S. Ozawa, J. Sawada, N. Kamatani, J. Furuse, H. Ishii, T. Yoshida, H. Ueno, T. Okusaka, and N. Saijo. 2007. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25:32-42.
41. Victoria, J. G., D. J. Lee, B. R. McDougall, and W. E. Robinson. 2003. Replication kinetics for divergent type 1 human immunodeficiency viruses using quantitative SYBR Green I real-time polymerase chain reaction. AIDS Res. Hum. Retroviruses 19:865-874.
42. Vodicka, M. A., W. C. Goh, L. I. Wu, M. E. Rogel, S. R. Bartz, V. L. Schweickart, C. J. Raport, and M. Emerman. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198.